{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T05:38:07Z","timestamp":1774330687798,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T00:00:00Z","timestamp":1704758400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T00:00:00Z","timestamp":1704758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002386","name":"Cairo University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002386","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Pediatr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Pulmonary arterial hypertension (PAH) in pediatrics is a progressive disease with significant vascular remodeling, right sided heart failure, and death if left untreated. Elevated interleukin-6 (IL-6) level in PAH patients is taken as an independent predictor of adverse outcome including mortality. The aim of this study was to investigate and compare serum levels of IL-6 in children with PAH and healthy matched controls, and correlate between IL-6 and degree of PAH, as well as mortality. IL-6 was measured by ELISA in serum samples in 40 children with PAH (age 1\u201312\u00a0years) and 40 age and sex-matched healthy controls. There was a statistically significant increase in IL-6 level among PAH cases compared with the controls (1.85\u00a0ng\/L vs 1.30\u00a0ng\/L,\n                    <jats:italic>p<\/jats:italic>\n                    -value\u2009=\u20090.004). IL-6 at cut off point 1.45\u00a0ng\/L significantly predict pulmonary hypertension in children (\n                    <jats:italic>AUC<\/jats:italic>\n                    \u2009=\u20090.685, 75% sensitivity, and 65% specificity with\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.002). There was no statistically significant association between IL-6 level and degree of PAH (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.218). There was no statistically significant association between IL-6 level and mortality (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.662).\n                  <\/jats:p>\n                  <jats:p>\n                    \u00a0 \u00a0\n                    <jats:italic>Conclusion<\/jats:italic>\n                    : IL-6 significantly predict PAH in pediatrics but there is no association between IL-6 level and degree of PAH or mortality. IL-6 may provide a less costly and less invasive method for disease detection.\n                    <jats:table-wrap>\n                      <jats:table>\n                        <jats:tbody>\n                          <jats:tr>\n                            <jats:td colspan=\"2\">\n                              <jats:bold>What is Known:<\/jats:bold>\n                              <jats:italic>\u2022 Definitive diagnosis of PAH is made by right heart catheterization, while echocardiography is the gold standard for tracking the course of the disease.<\/jats:italic>\n                            <\/jats:td>\n                          <\/jats:tr>\n                          <jats:tr>\n                            <jats:td colspan=\"2\">\n                              <jats:bold>What is New:<\/jats:bold>\n                              <jats:italic>\u2022 It was assumed that children with a diagnosis of PAH would have higher serum IL-6 levels than controls. Furthermore, an adverse relationship between the blood IL-6 level and PPAH was predicted.<\/jats:italic>\n                            <\/jats:td>\n                          <\/jats:tr>\n                        <\/jats:tbody>\n                      <\/jats:table>\n                    <\/jats:table-wrap>\n                  <\/jats:p>","DOI":"10.1007\/s00431-023-05413-2","type":"journal-article","created":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T02:02:43Z","timestamp":1704765763000},"page":"1637-1643","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Prognostic and diagnostic utility of interleukin-6 in pediatric pulmonary arterial hypertension \u2014 a case-control study"],"prefix":"10.1007","volume":"183","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9791-5685","authenticated-orcid":false,"given":"Mohamed Abdallah Abd El","family":"Megied","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed Ahmed","family":"Abouelhassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8904-6536","authenticated-orcid":false,"given":"Eman Saad Abd El Salam","family":"Hadwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,9]]},"reference":[{"issue":"1","key":"5413_CR1","doi-asserted-by":"publisher","first-page":"1802148","DOI":"10.1183\/13993003.02148-2018","volume":"53","author":"N Gali\u00e8","year":"2019","unstructured":"Gali\u00e8 N, McLaughlin VV, Rubin LJ, Simonneau G (2019) An overview of the 6th world symposium on pulmonary hypertension. Eur Respir J 53(1):1802148","journal-title":"Eur Respir J"},{"issue":"1","key":"5413_CR2","doi-asserted-by":"publisher","first-page":"1801916","DOI":"10.1183\/13993003.01916-2018","volume":"53","author":"EB Rosenzweig","year":"2019","unstructured":"Rosenzweig EB, Abman SH, Adatia I, Beghetti M, Bonnet D, Haworth S, Ivy DD, Berger RB (2019) Pediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management. Eur Respir J 53(1):1801916. https:\/\/doi.org\/10.1183\/13993003.01916-2018","journal-title":"Eur Respir J"},{"issue":"2","key":"5413_CR3","doi-asserted-by":"publisher","first-page":"286","DOI":"10.4103\/2045-8932.83456","volume":"1","author":"M Del Cerro","year":"2011","unstructured":"Del Cerro M, Abman S, Diaz G, Freudenthal A, Freudenthal F, Harikrishnan S, Haworth S, Ivy D, Lopes A, Raj J, Sandoval J, Stenmark K, Adatia I (2011) A consensus approach to the classification of pediatric pulmonary hypertensive vascular disease: report from the PVRI Pediatric Taskforce, Panama 2011. Pulm Circ 1(2):286\u2013298","journal-title":"Pulm Circ"},{"issue":"3","key":"5413_CR4","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.ccl.2016.04.005","volume":"34","author":"D Ivy","year":"2016","unstructured":"Ivy D (2016) Pulmonary hypertension in children. Cardiol Clin 34(3):451\u2013472","journal-title":"Cardiol Clin"},{"issue":"13","key":"5413_CR5","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1089\/ars.2018.7673","volume":"31","author":"O Rafikova","year":"2019","unstructured":"Rafikova O, Imad A, Ruslan R (2019) Focus on early events: pathogenesis of pulmonary arterial hypertension development. Antioxid Redox Signal 31(13):933\u2013953","journal-title":"Antioxid Redox Signal"},{"key":"5413_CR6","doi-asserted-by":"crossref","unstructured":"O'Byrne ML, Kennedy KF, Kanter JP, Berger JT, Glatz AC (2018) Risk factors for major early adverse events related to cardiac catheterization in children and young adults with pulmonary hypertension: an analysis of data from the IMPACT (Improving Adult and Congenital Treatment) registry.\u00a0J Am Heart Assoc\u00a07.5:e008142","DOI":"10.1161\/JAHA.117.008142"},{"key":"5413_CR7","doi-asserted-by":"crossref","unstructured":"Cappelleri JC, Hwang LJ, Mardekian J, Mychaskiw MA (2010) PCV138 Measurement properties of peak VO2 in children with pulmonary arterial hypertension. Value Health 7.13:A367","DOI":"10.1016\/S1098-3015(11)72479-2"},{"key":"5413_CR8","doi-asserted-by":"crossref","unstructured":"Erzurum S, Rounds S, Stevens T, Aldred M (2010) Strategic plan for lung vascular research: an NHLBI-ORDR workshop report.\u00a0Am J Respir Crit Care Med\u00a0182.12:1554\u20131562","DOI":"10.1164\/rccm.201006-0869WS"},{"issue":"4","key":"5413_CR9","doi-asserted-by":"publisher","first-page":"492","DOI":"10.4103\/2045-8932.105038","volume":"2","author":"N Dereddy","year":"2012","unstructured":"Dereddy N (2012) Associated inflammation or increased flow-mediated shear stress, but not pressure alone, disrupts endothelial caveolin-1 in infants with pulmonary hypertension. Pulm Circ 2(4):492\u2013500","journal-title":"Pulm Circ"},{"issue":"8","key":"5413_CR10","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1183\/09031936.93.03080910","volume":"3","author":"A Morice","year":"1990","unstructured":"Morice A (1990) Atrial natriuretic peptide in primary pulmonary hypertension. Eur Respir J 3(8):910\u2013913","journal-title":"Eur Respir J"},{"issue":"9","key":"5413_CR11","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1136\/thx.2008.106435","volume":"64","author":"S Hall","year":"2009","unstructured":"Hall S (2009) Contribution of inflammation to the pathology of idiopathic pulmonary arterial hypertension in children. Thorax 64(9):778\u2013783","journal-title":"Thorax"},{"key":"5413_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev.immunol.23.021704.115806","volume":"23","author":"T Kishimoto","year":"2005","unstructured":"Kishimoto T (2005) Interleukin-6: from basic science to medicine-40 years in immunology. Annu Rev Immunol 23:1","journal-title":"Annu Rev Immunol"},{"key":"5413_CR13","doi-asserted-by":"publisher","unstructured":"Duncan M, Wagner BD, Murray K, Allen J, Colvin K, Accurso FJ, Ivy DD (2012) Circulating cytokines and growth factors in pediatric pulmonary hypertension. Mediators Inflamm 2012 Article ID 143428. https:\/\/doi.org\/10.1155\/2012\/143428","DOI":"10.1155\/2012\/143428"},{"issue":"10","key":"5413_CR14","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a016295","volume":"6","author":"T Tanaka","year":"2014","unstructured":"Tanaka T, Masashi N, Tadamitsu K (2014) IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol 6(10):a016295","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"9","key":"5413_CR15","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.healun.2019.06.022","volume":"38","author":"G Hansmann","year":"2019","unstructured":"Hansmann G, Koestenberger M, Alastalo TP, Apitz C, Austin ED, Bonnet D, Budts W, D\u2019Alto M, Gatzoulis M, Hasan B (2019) \u20182019 updated consensus statement on the diagnosis and treatment of pediatric pulmonary hypertension: the European Pediatric Pulmonary Vascular Disease Network (EPPVDN), endorsed by AEPC, ESPR and ISHLT. J Heart Lung Transplant 38(9):879\u2013901","journal-title":"J Heart Lung Transplant"},{"issue":"19","key":"5413_CR16","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1016\/j.jacc.2020.03.047","volume":"75","author":"B Hasan","year":"2020","unstructured":"Hasan B, Hansmann G, Budts W, Heath A, Hoodbhoy Z, Jing ZC, Koestenberger M, Meinel K, Mocumbi A, Radchenko G (2020) Sallmon N Challenges and special aspects of pulmonary hypertension in middle-to low-income regions: JACC state-of-the-art review. J Am Coll Cardiol 75(19):2463\u20132477","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"5413_CR17","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1164\/rccm.201201-0049WS","volume":"185","author":"I Robbins","year":"2012","unstructured":"Robbins I, Moore T, Blaisdell C, Abman S (2012) Improving outcomes for pulmonary vascular disease. Am J Respir Crit Care Med 185(9):1015\u20131020","journal-title":"Am J Respir Crit Care Med"},{"key":"5413_CR18","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.jpeds.2020.04.041","volume":"223","author":"J Chen","year":"2020","unstructured":"Chen J (2020) Elevated interleukin-6 levels predict clinical worsening in pediatric pulmonary arterial hypertension. J Pediatr 223:164\u2013169","journal-title":"J Pediatr"},{"issue":"12","key":"5413_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11886-019-1229-2","volume":"21","author":"JE Ezekian","year":"2019","unstructured":"Ezekian JE, Hill KD (2019) Management of pulmonary arterial hypertension in the pediatric patient. Curr Cardiol Rep 21(12):1\u201311","journal-title":"Curr Cardiol Rep"},{"issue":"2","key":"5413_CR20","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1017\/S1047951116000408","volume":"27","author":"G Oz-Tuncer","year":"2017","unstructured":"Oz-Tuncer G (2017) The role of inflammatory biomarkers in CHD-associated pulmonary hypertension in children. Cardiol Young 27(2):255\u2013260","journal-title":"Cardiol Young"},{"issue":"3","key":"5413_CR21","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1183\/09031936.00174908","volume":"34","author":"N Selimovic","year":"2009","unstructured":"Selimovic N (2009) Growth factors and interleukin-6 across the lung circulation in pulmonary hypertension. Eur Respir J 34(3):662\u2013668","journal-title":"Eur Respir J"},{"issue":"5","key":"5413_CR22","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1164\/ajrccm.151.5.7735624","volume":"151","author":"M Humbert","year":"1995","unstructured":"Humbert M (1995) Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med 151(5):1628\u20131631","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"5413_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12931-021-01716-w","volume":"22","author":"T Koudstaal","year":"2021","unstructured":"Koudstaal T (2021) Plasma markers in pulmonary hypertension subgroups correlate with patient survival. Respir Res 22(1):1\u201313","journal-title":"Respir Res"},{"issue":"2","key":"5413_CR24","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1378\/chest.06-2207","volume":"131","author":"MM Hoeper","year":"2007","unstructured":"Hoeper MM, Welte T (2007) Systemic inflammation, COPD, and pulmonary hypertension. Chest 131(2):634\u2013635","journal-title":"Chest"},{"issue":"3","key":"5413_CR25","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.healun.2017.08.011","volume":"37","author":"W Prins","year":"2018","unstructured":"Prins W (2018) Interleukin-6 is independently associated with right ventricular function in pulmonary arterial hypertension. J Heart Lung Transplant 37(3):376\u2013384","journal-title":"J Heart Lung Transplant"},{"issue":"9","key":"5413_CR26","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1161\/CIRCULATIONAHA.109.933762","volume":"122","author":"E Soon","year":"2010","unstructured":"Soon E, Holmes A, Treacy C, Doughty N, Southgate L, Machado R, Trembath R, Jenning S, Barker L, Nicklin P, Walker C, Budd D, Pepke-Zaba J, Morrell N (2010) Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. Circulation 122(9):920\u2013927","journal-title":"Circulation"},{"issue":"2","key":"5413_CR27","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1161\/CIRCRESAHA.108.182014","volume":"104","author":"M Steiner","year":"2009","unstructured":"Steiner M (2009) Interleukin-6 overexpression induces pulmonary hypertension. Circ Res 104(2):236\u2013244","journal-title":"Circ Res"},{"issue":"3","key":"5413_CR28","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1183\/09031936.00151313","volume":"43","author":"J Cracowski","year":"2014","unstructured":"Cracowski J (2014) Proinflammatory cytokine levels are linked to death in pulmonary arterial hypertension. Eur Respir J 43(3):915\u2013917","journal-title":"Eur Respir J"},{"issue":"3","key":"5413_CR29","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1183\/09031936.00164713","volume":"43","author":"G Heresi","year":"2014","unstructured":"Heresi G, Aytekin M, Hammel J, Wang S, Chatterjee S (2014) Dweik R Plasma interleukin-6 adds prognostic information in pulmonary arterial hypertension. Eur Respir J 43(3):912\u2013914","journal-title":"Eur Respir J"}],"container-title":["European Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-023-05413-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00431-023-05413-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-023-05413-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T09:08:41Z","timestamp":1712567321000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00431-023-05413-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,9]]},"references-count":29,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["5413"],"URL":"https:\/\/doi.org\/10.1007\/s00431-023-05413-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3262905\/v1","asserted-by":"object"}]},"ISSN":["1432-1076"],"issn-type":[{"value":"1432-1076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,9]]},"assertion":[{"value":"14 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the declaration of Helsinki and approved by the Institutional Ethical Review Board (MS-360-2021), Faculty of Medicine, Cairo University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable (no individual details, images or videos).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}]}}